CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Purdue Pharma L.P. v. IMPAX Laboratories, Inc.

1:13-cv-00763

Overview

Case Number 1:13-cv-00763
Filing Date 2013-02-01
Status Terminated
Termination Date 2013-12-06
Court District Court, S.D. New York (nysd)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Plaintiff

IMPAX Laboratories, Inc. Operating Company

Represented By

1 Attorneys Listed

Counter Defendant

Grunenthal GMBH NPE (Individual / Inventor)

Represented By

6 Attorneys Listed

Eric Brian LaMons

Wilk Auslander LLP

Tel: +1 (212) 981-2295
Fax: +1 (212) 752-6380

1515 Broadway, 43rd Floor, New York, NY 10036

Purdue Pharma L.P. NPE (University / Research)

Represented By

2 Attorneys Listed

Court & Judges

Court

District Court, S.D. New York (nysd)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 9 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts Counterparts in force
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (9): πŸ‡©πŸ‡ͺ Germany πŸ‡ΊπŸ‡Έ US
Parallel Proceedings Across Jurisdictions (0 found):

No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.

Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

1 Patent

There is a single patent involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US8309060
Abuse-proofed dosage form
Filed: 2012-01-09
Issued: 2012-11-13
Active (5.1 yrs remaining)
Expires: 2032-01-09

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Active Threat

Active Threat β€” Patent is within enforceable statutory term. Patentee retains legal standing to seek permanent injunctive relief and exclusion orders.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term β€” No obviousness-type double patenting truncation noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. 4th & 8th Year Maintenance Fees Paid (12th Year Window Upcoming).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

4

Dispositive

1

Granted

0

Denied

0

Pending / Review

4

Motions by Category

Claim Construction / Markman Filing 3 Motion for Preliminary Injunction / TRO 1

Key Dispositive Motions & Rulings

Motion for Preliminary Injunction / TRO Pending / Under Review
ORDER: On May 31, 2013, the parties in the above-captioned actions filed a joint proposed discovery plan pursuant to Rule 26(f) of the Federal Rules of Civil Pr...
Entry #28 • 2013-08-14 Document →
Claim Construction / Markman Filing Pending / Under Review
ORDER: It is hereby ordered that the parties shall submit to the Court by May 31, 2013, a proposed schedule for these actions, including a joint discovery plan ...
Entry #25 • 2013-05-08 Document →
Claim Construction / Markman Filing Pending / Under Review
ORDER: On July 15, 2013, at 9:30 a.m., the Court will hold a Markman hearing to construe the claims at issue in the patents listed herein. The Markman hearing w...
Entry #26 • 2013-05-08 Document →
Claim Construction / Markman Filing Pending / Under Review
ORDER: A pretrial status conference in the above matters is set for May 7, 2013, at 3:00 p.m. The parties in each action are directed to confer in advance of th...
Entry #24 • 2013-04-19 Document →

Docket Entries

(34 total)
Pleading / Complaint

COMPLAINT against IMPAX Laboratories, Inc. (Filing Fee $ 350.00, Receipt Number 1059116)Document filed by Purdue Pharma L.P., Grunenthal GMBH. (Attachments: # 1 a, # 2 b)(laq) (Entered: 02/04/2013)

Entry #1 • 2013-02-01
1
Pleading / Complaint

COMPLAINT against IMPAX Laboratories, Inc. (Filing Fee $ 350.00, Receipt Number 1059116)Document filed by Purdue Pharma L.P., Grunenthal GMBH. (Attachments: # 1 a, # 2 b)(laq) (Entered: 02/04/2013)

Entry #1 • 2013-02-01
2
Pleading / Complaint

COMPLAINT against IMPAX Laboratories, Inc. (Filing Fee $ 350.00, Receipt Number 1059116)Document filed by Purdue Pharma L.P., Grunenthal GMBH. (Attachments: # 1 a, # 2 b)(laq) (Entered: 02/04/2013)

Entry #1 • 2013-02-01
2
Court Order

STANDING ORDER IN RE PILOT PROJECT REGARDING CASE MANAGEMENT TECHNIQUES FOR COMPLEX CIVIL CASES IN THE SOUTHERN DISTRICT OF NEW YORK (See M-10-468 Order filed November 1, 2011). This case is hereby designated for inclusion in the Pilot Project Regarding Case Management Techniques for Complex Civil Cases in the Southern District of New York (the Pilot Project), unless the judge to whom this case is assigned determines otherwise. This case is designated for inclusion in the Pilot Project because it is a class action, an MDL action, or is in one of the following Nature of Suit categories: 160, 245, 315, 355, 365, 385, 410, 830, 840, 850, 893, or 950. The presiding judge in a case that does not otherwise qualify for inclusion in the Pilot Project may nevertheless designate the case for inclusion in the Pilot Project by issuing an order directing that the case be included in the Pilot Project. The description of the Pilot Project, including procedures to be followed, is attached to this Order. (Signed by Judge Loretta A. Preska on 10/31/11) (laq) (Entered: 02/04/2013)

Entry #2 • 2013-02-01
1

RULE 7.1 CORPORATE DISCLOSURE STATEMENT. Identifying Other Affiliate Purdue Holdings L.P. for Purdue Pharma L.P.. Document filed by Purdue Pharma L.P..(Hendler, Pablo) (Entered: 02/05/2013)

Entry #3 • 2013-02-05
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc